drugset / Trial / NCT02358200
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
Open label, non-randomized, dose escalation and expansion Phase Ia/b trial to evaluate the safety of the combination of BMN 673 and carboplatin, and subsequently BMN 673 in combination with paclitaxel and carboplatin to determine the recommended Phase II dose of the combination.
Timeline
- Start
- 2015-02-23
- Primary completion
- 2019-01-08
- Completion
- 2019-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 750 ug | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Talazoparib | Small molecule | — | Oral |